Breaking News Instant updates and real-time market news.

PFE

Pfizer

$31.67

0.1346 (0.43%)

, CMA

Comerica

$62.18

1.05 (1.72%)

10:36
11/29/16
11/29
10:36
11/29/16
10:36

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying he sees a greater likelihood that Pfizer will be able to access its cash overseas under the new administration, which could be used to acquire growth assets and return capital to shareholders. 2. Comerica (CMA) upgraded to Outperform from Market Perform at Keefe Bruyette. 3. Tractor Supply (TSCO) upgraded to Buy from Neutral at Northcoast with analyst Chuck Cerankosky saying he expects the company to benefit from colder weather and the improving US economy and said product assortments and promotions have also been adjusted to the new economics of the energy patch and its impact on this company's customers. 4. Del Frisco's (DFRG) upgraded to Outperform from Neutral at Credit Suisse with analyst Jason West saying it is a key beneficiary of improved high-end consumer and corporate spending. 5. Veracyte upgraded to Buy from Neutral at Janney Capital with analyst Paul Knight saying the company's "disciplined test development, commercialization, and reimbursement processes" insulate it from a number of problems plaguing the pharma sector. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

PFE

Pfizer

$31.67

0.1346 (0.43%)

CMA

Comerica

$62.18

1.05 (1.72%)

TSCO

Tractor Supply

$74.92

0.31 (0.42%)

DFRG

Del Frisco's

$16.35

-0.4 (-2.39%)

VCYT

Veracyte

$7.68

-0.07 (-0.90%)

  • 29

    Nov

  • 29

    Nov

  • 30

    Nov

  • 04

    Dec

  • 09

    Jan

PFE Pfizer
$31.67

0.1346 (0.43%)

11/29/16
LEHM
11/29/16
UPGRADE
Target $38
LEHM
Overweight
Pfizer upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Pfizer to Overweight and raised its price target to $38 from $37. Meacham sees a greater likelihood that Pfizer will be able to access its cash overseas under the new administration, which could be used to acquire growth assets and return capital to shareholders.
11/02/16
11/02/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Hold from Buy at Argus and to Market Perform from Outperform at BMO Capital. 2. BP (BP) downgraded to Hold from Buy at Societe Generale. 3. Corning (GLW) downgraded to Buy from Conviction Buy at Goldman with analyst Doug Clark saying the restocking phase of glass/TV cyclical recovery is now "well understood and largely behind us." 4. Adeptus Health (ADPT) downgraded to Underperform from Buy at BofA/Merrill, to Hold from Buy at Jefferies, and to Equal Weight from Overweight at Stephens. 5. Brookdale Senior Living (BKD) downgraded to Underperform from Neutral at BofA/Merrill, to Market Perform from Outperform at Wells Fargo, and to Outperform from Top Pick at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/02/16
ARGS
11/02/16
DOWNGRADE
ARGS
Hold
Pfizer downgradedon weaker outlook at Argus
As noted earlier, Argus downgraded Pfizer to Hold from Buy. Analyst Jacob Kilstein cited "recent pipeline setbacks, prospects for increased competition, and management's decision to shelve its business separation plan" as reasons for the downgrade.
11/02/16
LEER
11/02/16
NO CHANGE
LEER
Pfizer boco failure should not spillover to other PCSK9 antibodies, says Leerink
Leerink analyst Geoffrey Porges says that Pfizer's (PFE) announcement that it is discontinuing development of anti-PCSK9 antibody bococizumab is significant and may give investors pause regarding the entire anti-PCSK9 antibody class. However, the analyst notes that composite of views suggests Boco-specific factors led to disappointment and to the program discontinuation. Further, Porges does not believes investors should expect any similar effects in the longer term follow up with Amgen's (AMGN) Repatha or Regeneron (REGN)/Sanofi's (SNY) Praluent.
CMA Comerica
$62.18

1.05 (1.72%)

11/29/16
KBWI
11/29/16
UPGRADE
Target $68
KBWI
Outperform
Comerica upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Klock upgraded Comerica to Outperform to reflect his shift towards banks that have the best positioning in a rising rate environment. The analyst raised his price target for the shares to $68 from $53.
11/28/16
11/28/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Deere (DE) upgraded to Neutral from Underweight at Piper Jaffray with analyst Brett Wong saying investors will likely continue to pay "lofty multiples" since a bottom of the cycle is close. 2. ConocoPhillips (COP) upgraded to Conviction Buy from Neutral at Goldman with analyst Neil Mehta saying ConocoPhillips offers the most attractive free cash yield among U.S. majors/E&P and believes the company will grow its production through the ned of the decade. 3. Comerica (CMA) upgraded to Buy from Hold at Jefferies with analyst Ken Usdin saying the company's earnings are likely to benefit more than peers from higher short-term interest rates and a potentially lower Federal tax rate. 4. DuPont Fabros (DFT) upgraded to Outperform from Neutral at Baird with analyst David Rodgers citing its future development opportunity, solid corporate execution, and valuation. 5. Horizon Pharma (HZNP) upgraded to Buy from Neutral at Citi analyst Liav Abraham saying the risk/reward as favorable into the upcoming pivotal data for Actimmune in Friederich's Ataxia. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/28/16
JEFF
11/28/16
UPGRADE
Target $74
JEFF
Buy
Comerica upgraded to Buy from Hold at Jefferies
Jefferies analyst Ken Usdin upgraded Comerica to Buy saying the company's earnings are likely to benefit more than peers from higher short-term interest rates and a potentially lower Federal tax rate. The analyst raised his price target for the shares to $74 from $56.
11/14/16
SDLR
11/14/16
DOWNGRADE
Target $60
SDLR
Hold
Comerica downgraded to Hold from Buy at Sandler O'Neill
Sandler O'Neill analyst Scott Siefers downgraded Comercia to Hold with a $60 price target citing recent shares strength.
TSCO Tractor Supply
$74.92

0.31 (0.42%)

10/20/16
OPCO
10/20/16
NO CHANGE
Target $80
OPCO
Outperform
Oppenheimer sees Tractor Supply weakness as buying opportunity
Oppenheimer analyst Brian Nagel notes that Tractor Supply's Q3 results were consistent with the company's prior negative pre-announcement. The analyst sees the recent pullback in the shares as a "significant" intermediate-term buying opportunity for investors. Nagel believes the combination of washed-out near-term sentiment and his view that recent sales woes are more cyclical than structural implies that while Tractor Supply could languish a bit longer, the next major move for the stock is apt to prove to the upside. He reiterates an Outperform rating and $80 price target on the shares.
10/20/16
10/20/16
NO CHANGE

Tractor Supply should be bought on weakness, says SunTrust
After Tractor Supply reported results that were in-line with its preannouncement but said its incentive compensation would rise next year, SunTrust analyst David Magee characterizes the incentive compensation increase and weak oil/ag markets as "temporary pressures." The analyst doesn't believe that the company is losing share, and he recommends buying the stock on weakness.
10/28/16
ARGS
10/28/16
DOWNGRADE
ARGS
Hold
Tractor Supply downgraded to Hold from Buy at Argus
Argus analyst John Staszak downgraded Tractor Supply to Hold following the Q3 report that said weakness in the energy and agricultural sectors had hurt consumer spending and company revenue in the South and Midwest. The analyst lowered estimates to reflect weak demand and the impact from decelerating comps.
11/29/16
NRCS
11/29/16
UPGRADE
NRCS
Buy
Tractor Supply upgraded to Buy from Neutral at Northcoast
Northcoast analyst Chuck Cerankosky upgraded Tractor Supply to Buy with a $102 price target. The analyst expects the company to benefit from colder weather and the improving US economy and said product assortments and promotions have also been adjusted to the new economics of the energy patch and its impact on this company's customers.
DFRG Del Frisco's
$16.35

-0.4 (-2.39%)

07/26/16
STFL
07/26/16
DOWNGRADE
STFL
Hold
Del Frisco's downgraded to Hold from Buy at Stifel
Stifel analyst Paul Westra downgraded Del frisco's based on the firm's belief that the U.S. economy will probably enter a recession within nine months. As a result, the firm now expects two year industrywide comps to come in at 0.5% in the first half of 2018, versus the consensus outlook of 1.75%, Westra stated.
08/22/16
ADAM
08/22/16
INITIATION
Target $16
ADAM
Hold
Del Frisco's initiated with a Hold at Canaccord
Canaccord analyst Lynne Collier initiated Del Frisco's with a Hold rating and $16 price target.
11/16/16
SPHN
11/16/16
DOWNGRADE
SPHN
Equal Weight
Del Frisco's downgraded to Equal Weight from Overweight at Stephens
11/29/16
FBCO
11/29/16
UPGRADE
FBCO
Outperform
Del Frisco's upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Jason West upgraded Del Frisco's to Outperform and raised its price target to $19 from $15 saying it is a key beneficiary of improved high-end consumer and corporate spending. West said Del Frisco's is the most effective way to gain exposure to several of Trump's stated priorities of individual and corporate tax reform, resulting in increased disposable income and revitalized business spending.
VCYT Veracyte
$7.68

-0.07 (-0.90%)

11/22/16
LEER
11/22/16
NO CHANGE
Target $12
LEER
Outperform
CLFS 2017 rates a clear positive for Veracyte, says Leerink
Leerink analyst Puneet Souda notes that the Centers for Medicare and Medicaid Services, or CMS, released its Clinical Laboratory Fee Schedules, or CLFS, final determination or final pricing on a number of tests for 2017 including Veracyte's Afirma. The analyst sees the company's Afirma Thyroid FNA GEC pricing increase as a clear positive for Veracyte as it eliminates both near-term uncertainty and saves the company from an expected $1.6M impact in 2017. He reiterates an Outperform rating and $12 price target on the shares.
11/29/16
PIPR
11/29/16
NO CHANGE
PIPR
Piper sees tax holiday as potential catalyst for Medical Diagnostics space
A repatriation tax holiday represents a potential catalyst for the Medical Diagnostics space, Piper Jaffray analyst William Quirk tells investors in a research note. Quirk notes that Becton Dickinson (BDX), Illumina (ILMN) and PerkinElmer (PKI) disclose cash held overseas and that all have highlighted share repurchases and acquisitions as priorities. He believes a repatriation event could be a catalyst for small lab deals. Acquisition targets include CareDx (CDNA), Genomic Health (GHDX), Oxford Immunotec (OXFD), Trovagene (TROV) and Veracyte (VCYT), Quirk tells investors.
11/29/16
JANY
11/29/16
UPGRADE
JANY
Buy
Veracyte upgraded to Buy from Neutral at Janney Capital
11/29/16
JANY
11/29/16
UPGRADE
JANY
Buy
Veracyte upgraded at Janney Capital
As noted earlier, Janney Capital upgraded Veracyte to Buy from Neutral. Analyst Paul Knight says that the company's "disciplined test development, commercialization, and reimbursement processes" insulate it from a number of problems plaguing the pharma sector. He thinks that recent regulatory changes have "dramatically reduced" the company's pricing risk. Target to $16 from $8.

TODAY'S FREE FLY STORIES

ETSY

Etsy

$12.72

0.21 (1.68%)

, SHOP

Shopify

$61.75

-0.98 (-1.56%)

08:40
02/27/17
02/27
08:40
02/27/17
08:40
Recommendations
Etsy, Shopify, Stamps.com analyst commentary  »

Several data points…

ETSY

Etsy

$12.72

0.21 (1.68%)

SHOP

Shopify

$61.75

-0.98 (-1.56%)

STMP

Stamps.com

$131.60

-2.15 (-1.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

08:40
02/27/17
02/27
08:40
02/27/17
08:40
General news
U.S. durable goods orders rebounded 1.8% in January »

U.S. durable goods orders…

ERIC

Ericsson

$6.45

-0.08 (-1.23%)

, QCOM

Qualcomm

$57.22

0.08 (0.14%)

08:39
02/27/17
02/27
08:39
02/27/17
08:39
Conference/Events
Drexel Hamilton Events at Mobile World Congress »

Meetings with various…

ERIC

Ericsson

$6.45

-0.08 (-1.23%)

QCOM

Qualcomm

$57.22

0.08 (0.14%)

CSCO

Cisco

$34.32

0.28 (0.82%)

SNCR

Synchronoss

$30.49

-0.37 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 03

    Mar

  • 13

    Mar

  • 29

    Mar

REGN

Regeneron

$361.01

0.05 (0.01%)

, SNY

Sanofi

$42.70

0.19 (0.45%)

08:39
02/27/17
02/27
08:39
02/27/17
08:39
Hot Stocks
Regeneron, Sanofi to present new data on DUPIXENT at AAD »

Regeneron Pharmaceuticals…

REGN

Regeneron

$361.01

0.05 (0.01%)

SNY

Sanofi

$42.70

0.19 (0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

  • 09

    Mar

  • 17

    Mar

  • 29

    Mar

LAUR

Laureate Education

$13.24

0.06 (0.46%)

08:38
02/27/17
02/27
08:38
02/27/17
08:38
Initiation
Laureate Education initiated  »

Laureate Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$21.60

0.02 (0.09%)

08:37
02/27/17
02/27
08:37
02/27/17
08:37
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNB

F.N.B.

$15.65

-0.02 (-0.13%)

, YDKN

Yadkin Financial

$33.42

-0.14 (-0.42%)

08:37
02/27/17
02/27
08:37
02/27/17
08:37
Hot Stocks
F.N.B. receives final regulatory approvals for proposed merger of Yadkin Financial »

F.N.B. (FNB) announced…

FNB

F.N.B.

$15.65

-0.02 (-0.13%)

YDKN

Yadkin Financial

$33.42

-0.14 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENB

Enbridge

$41.34

-0.37 (-0.89%)

, SE

Spectra Energy

$40.68

-0.32 (-0.78%)

08:36
02/27/17
02/27
08:36
02/27/17
08:36
Hot Stocks
Enbridge, Spectra Energy complete merger »

Enbridge (ENB) announced…

ENB

Enbridge

$41.34

-0.37 (-0.89%)

SE

Spectra Energy

$40.68

-0.32 (-0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

OTIV

On Track Innovations

$1.99

-0.08 (-3.86%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Hot Stocks
On Track Innovations announces appointment of VP of Sales »

On Track Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$52.63

0.12 (0.23%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EV

Eaton Vance

$46.96

-0.24 (-0.51%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Hot Stocks
Eaton Vance expands presence in Japan »

Eaton Vance announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRI

Silver Standard

$11.53

0.63 (5.78%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Recommendations
Silver Standard analyst commentary  »

Silver Standard reproted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$57.81

-0.68 (-1.16%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Hot Stocks
Buffett says Wells Fargo made 'huge mistake' »

Warren Buffett said on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

XLE

Energy Select Sector SPDR

$70.99

-0.67 (-0.93%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:35
02/27/17
02/27
08:35
02/27/17
08:35
General news
N.Y. FX Outlook »

N.Y. FX Outlook: The…

XLY

Consumer Discretionary Sector SPDR

$86.92

0.4 (0.46%)

08:34
02/27/17
02/27
08:34
02/27/17
08:34
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENFC

Entegra Financial

$23.15

0.05 (0.22%)

08:34
02/27/17
02/27
08:34
02/27/17
08:34
Hot Stocks
Entegra Financial completes purchase of 2 branches in Northern Georgia »

Entegra Bank, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$52.43

0.11 (0.21%)

08:34
02/27/17
02/27
08:34
02/27/17
08:34
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$51.59

0.77 (1.52%)

08:33
02/27/17
02/27
08:33
02/27/17
08:33
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMPE

Ampio

$0.80

-0.0312 (-3.75%)

08:33
02/27/17
02/27
08:33
02/27/17
08:33
Hot Stocks
Ampio: OTAT provides guidance for path to approval of Ampion »

Ampio Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLSN

Celsion

$0.21

-0.0229 (-9.83%)

08:33
02/27/17
02/27
08:33
02/27/17
08:33
Hot Stocks
Celsion sees OVATION study to be fully enrolled, data to come in Q2 »

Celsion Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$55.28

0.19 (0.34%)

08:33
02/27/17
02/27
08:33
02/27/17
08:33
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$74.78

0.36 (0.48%)

08:33
02/27/17
02/27
08:33
02/27/17
08:33
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$30.49

-0.37 (-1.20%)

08:32
02/27/17
02/27
08:32
02/27/17
08:32
Hot Stocks
Synchronoss names John Frederick as CFO, effective immediately »

Synchronoss Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

IWM

iShares Trust Russell 2000 Index Fund

$138.65

-0.1 (-0.07%)

08:32
02/27/17
02/27
08:32
02/27/17
08:32
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.